Skip to main content
Kringle Pharma,Inc. logo

Kringle Pharma,Inc. — Investor Relations & Filings

Ticker · 4884 ISIN · JP3270790003 T Manufacturing
Open in API
Filings indexed 53 across all filing types
Latest filing 2023-05-15 Report Publication Anno…
Country JP Japan
Listing T 4884

About Kringle Pharma,Inc.

https://www.kringle-pharma.com/en/

Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on the research and development of regenerative medicines for intractable and rare diseases. The company's core technology is based on recombinant human Hepatocyte Growth Factor (HGF), an endogenous protein with tissue-protective, regenerative, and repairing functions. Kringle Pharma has established a platform to manufacture pharmaceutical-grade HGF protein and is conducting clinical trials for several indications. Key development programs target conditions including acute spinal cord injury, vocal fold scarring, and Amyotrophic Lateral Sclerosis (ALS).

Recent filings

Filing Released Lang Actions
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically related to the accuracy of the Second Quarter Report (第２四半期報告書). While it references a quarterly report, the document itself is a regulatory confirmation statement required by Japanese law to accompany the filing. Since it is a specific regulatory filing that does not fit into the primary financial report categories (like 10-K or IR) and is not a mere announcement of a report, it falls under the Regulatory Filings category.
2023-05-15 Japanese
四半期報告書－第22期第2四半期(2023/01/01－2023/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Kringle Pharma, Inc. in accordance with the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, management analysis (MDA), and operational updates for the second quarter of the 22nd fiscal period (ending March 31, 2023). As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report (IR). Q2 2022
2023-05-15 Japanese
四半期報告書－第22期第1四半期(2022/10/01－2022/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Kringle Pharma, Inc., covering the period from October 1, 2022, to December 31, 2022. It contains detailed financial statements (balance sheet, income statement), management analysis of financial conditions, and business results. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-02-10 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly states it is filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of a quarterly report, rather than the quarterly report itself. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. Q1 2023
2023-02-10 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It serves as a formal certification by the CEO and CFO regarding the accuracy of the company's Annual Securities Report (Yuuka Shouken Houkokusho). Since it is a regulatory filing required by law to accompany financial reporting but does not constitute the financial report itself, and does not fit into specific categories like earnings releases or board changes, it is classified as a general regulatory filing. FY 2022
2022-12-26 Japanese
有価証券報告書－第21期(令和3年10月1日－令和4年9月30日)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains the official header, fiscal period (2021-10-01 to 2022-09-30), company information, and detailed financial statements/business analysis. It is a comprehensive annual filing, not an announcement or a summary. FY 2022
2022-12-26 Japanese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.